Blog
RSS FeedPosted by Michael Wonder on 15 Aug 2022
argenx announces European Commission approval of Vyvgart (efgartigimod alfa-fcab) for the treatment of generalised myasthenia gravis
11 August 2022 - Vyvgart is the first neonatal Fc receptor blocker approved in Europe for the treatment of adults living ...
Posted by Michael Wonder on 15 Aug 2022
Calls for decision on Trikafta as new advice shows health system savings and decades more life for patients
15 August 2022 - Pressure is mounting on the Government to make a decision on whether it will fund the ...
Posted by Michael Wonder on 15 Aug 2022
PHARMAC shares update on its assessment of Trikafta
15 August 2022 - PHARMAC has today published the latest record of advice from PTAC and, for the first time, has ...
Posted by Michael Wonder on 14 Aug 2022
Economic cost and sustainability of oral therapies in precision oncology
12 August 2022 - Precision oncology promises improved outcomes but the cost effectiveness and accessibility of targeted therapies is debatable. ...
Posted by Michael Wonder on 14 Aug 2022
FDA approves first medicine under new Project Optimus
12 August 2022 - Project Optimus is another initiative of the FDA Oncology Center of Excellence. ...
Posted by Michael Wonder on 13 Aug 2022
Restrictions put on diabetes drug Ozempic leave users feeling ‘fat shamed’
13 August 2022 - A drug that caused a buzz for its ability to help people shed kilos has now been ...
Posted by Michael Wonder on 12 Aug 2022
Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld
12 August 2022 - Half a million people in the UK with conditions like blood cancer that prevents them being ...
Posted by Michael Wonder on 12 Aug 2022
US move to negotiate drug prices a rare defeat for big pharma
12 August 2022 - Big pharma spent more than any other industry to lobby Congress and federal agencies this year, ...
Posted by Michael Wonder on 12 Aug 2022
NICE recommendation expands patient eligibility for AbbVie’s Ozurdex
12 August 2022 - Treatment becomes an option for treating visual impairment caused by diabetic macular oedema, regardless of lens ...
Posted by Michael Wonder on 12 Aug 2022
For the second time, Pfizer tries a warranty in response to concerns over high drug costs
8 August 2022 - For only the second time, Pfizer is offering a warranty for a medicine that will cover ...
Posted by Michael Wonder on 12 Aug 2022
Enhertu approved in the U.S. as the first HER2 directed therapy for patients with previously treated HER2 mutant metastatic non-small-cell lung cancer
12 August 2022 - Based on DESTINY-Lung02 results which showed Daiichi Sankyo and AstraZeneca’s Enhertu reported a confirmed objective response ...
Posted by Michael Wonder on 11 Aug 2022
Lynparza receives Health Canada approval as adjuvant treatment for patients with germline BRCA mutated HER2 negative high-risk early breast cancer
11 August 2022 - First and only approved medicine targeting germline BRCA mutations in high-risk early breast cancer. ...
Posted by Michael Wonder on 11 Aug 2022
FDA approves capmatinib for metastatic non-small-cell lung cancer
11 August 2022 - On August 10, 2022, the FDA granted regular approval to capmatinib (Tabrecta, Novartis) for adult patients ...
Posted by Michael Wonder on 11 Aug 2022
SMC approve Johnson & Johnson’s systemic light chain amyloidosis therapy
10 August 2022 - Newly diagnosed patients will become the first to access systemic light chain amyloidosis treatment in the ...
Posted by Michael Wonder on 11 Aug 2022
MHRA grants marketing authorisation for Novartis’ radioligand therapy Pluvicto (lutetium (Lu 177) vipivotide tetraxetan) in advanced prostate cancer in Great Britain
11 August 2022 - Locamet (gozetotide), a PSMA targeted positron emission tomography imaging tracer, has also received a licence from the ...